Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• NP638325.RAYgwazOZLdqEX04EvfFQkfO-rONiSTViDJ6FCBaYhHwc130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP638325.RAYgwazOZLdqEX04EvfFQkfO-rONiSTViDJ6FCBaYhHwc130_provenance.
• NP751805.RARupA-ByrtFbmpABNQ7O79uCKHyvCPZL0dUP6WwM-7yQ130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP751805.RARupA-ByrtFbmpABNQ7O79uCKHyvCPZL0dUP6WwM-7yQ130_provenance.
• NP156758.RAdAglAfA_bZbZ_eXuOtuEetJD50chuvrocyF7NS6S3qo130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP156758.RAdAglAfA_bZbZ_eXuOtuEetJD50chuvrocyF7NS6S3qo130_provenance.
• NP933832.RAcy4qGUQVGJpwOfU8F_6dMWd1oivjApWXXmhPsjgTDWU130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP933832.RAcy4qGUQVGJpwOfU8F_6dMWd1oivjApWXXmhPsjgTDWU130_provenance.
• NP934879.RAc_OO6zuwmTtLjuJSE9Vk8zEoyfkNJBTIEIT7hZ8310s130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP934879.RAc_OO6zuwmTtLjuJSE9Vk8zEoyfkNJBTIEIT7hZ8310s130_provenance.
• NP804624.RAnjhpNsFhg38K8_0nIU4tBQzzaRdQiP3a4ivifkyozjI130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP804624.RAnjhpNsFhg38K8_0nIU4tBQzzaRdQiP3a4ivifkyozjI130_provenance.
• NP508229.RARRDE4q-SyewsCB9kCGI7ThIUrMMdZ8QRMQNRS_JIW0M130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP508229.RARRDE4q-SyewsCB9kCGI7ThIUrMMdZ8QRMQNRS_JIW0M130_provenance.
• NP610706.RAWseidDuQw7P4SO8dnfcQswZ4E3Ohaddv8oSxFG0dH8Y130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP610706.RAWseidDuQw7P4SO8dnfcQswZ4E3Ohaddv8oSxFG0dH8Y130_provenance.
• NP714773.RAT9ZKmCSmXdDxqxEBt3PLFKlHFs6Y5XZqog8UB5BXhu0130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP714773.RAT9ZKmCSmXdDxqxEBt3PLFKlHFs6Y5XZqog8UB5BXhu0130_provenance.
• NP703710.RAwiJdVZ_vfzBx8_FzlI8E7UZmznuSeyzA35Tc2NEEZUE130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP703710.RAwiJdVZ_vfzBx8_FzlI8E7UZmznuSeyzA35Tc2NEEZUE130_provenance.
• NP799159.RA9fdL8Lsx8SeFmxpZ3QruqrlYzQUzeGzwNYw2GOWrijU130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP799159.RA9fdL8Lsx8SeFmxpZ3QruqrlYzQUzeGzwNYw2GOWrijU130_provenance.
• NP830574.RA3GwbimmZGwfLufVkCwxnncunGqEL3Zs1y1FyAkSxo8U130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP830574.RA3GwbimmZGwfLufVkCwxnncunGqEL3Zs1y1FyAkSxo8U130_provenance.
• NP908070.RA09vQe-NmJjniDrKC1qKiAQ1wW_dpP-G6TkXvK7s6HXg130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP908070.RA09vQe-NmJjniDrKC1qKiAQ1wW_dpP-G6TkXvK7s6HXg130_provenance.
• NP724309.RAbUquJVxk05w9YwGjGyVJV7cTUOByg_AiAfIA-gZmcAc130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724309.RAbUquJVxk05w9YwGjGyVJV7cTUOByg_AiAfIA-gZmcAc130_provenance.
• NP724310.RAcXsktUIPSv6pZ3Nc_SVOsOOD9xxXuqDrg_1WiahYK5E130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724310.RAcXsktUIPSv6pZ3Nc_SVOsOOD9xxXuqDrg_1WiahYK5E130_provenance.
• NP724319.RAb_B7u_22cBoYaPuQhJNiCU1hc50nRuKB-EZvt5Rs7wM130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724319.RAb_B7u_22cBoYaPuQhJNiCU1hc50nRuKB-EZvt5Rs7wM130_provenance.
• NP724320.RASavojTGd-Zj8cHvsbFpVSi2EORgPPAxdQVbvEeb0SFw130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724320.RASavojTGd-Zj8cHvsbFpVSi2EORgPPAxdQVbvEeb0SFw130_provenance.
• NP581120.RAHrJJ3nubsDhatobcYUqsuRqCnFjEehffGMyldzEGdpY130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP581120.RAHrJJ3nubsDhatobcYUqsuRqCnFjEehffGMyldzEGdpY130_provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP773618.RAhWNUdeWUjeMwb3Tewd_5MbPjbBLRnx4lqqX9zptr4wE130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP773618.RAhWNUdeWUjeMwb3Tewd_5MbPjbBLRnx4lqqX9zptr4wE130_provenance.
• NP1414031.RAeGg5QNDLO-taiKffLXGaCs_B7kIOUNM2AgU_Bp81SH8130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414031.RAeGg5QNDLO-taiKffLXGaCs_B7kIOUNM2AgU_Bp81SH8130_provenance.
• NP1414032.RAeWxbvb8bgeKztG9cvdIzW9_DfQIHXcBFsHgBOdp3xTg130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414032.RAeWxbvb8bgeKztG9cvdIzW9_DfQIHXcBFsHgBOdp3xTg130_provenance.
• NP1414034.RAR-YKTfw5mcSX_iZdgTzCubX1NC96qmLCPPUWzpEgu4E130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414034.RAR-YKTfw5mcSX_iZdgTzCubX1NC96qmLCPPUWzpEgu4E130_provenance.
• NP1414035.RAXG2OjclXFel07GaJAKoXsYwAZwku1Zr0TfTEEvWwQjw130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414035.RAXG2OjclXFel07GaJAKoXsYwAZwku1Zr0TfTEEvWwQjw130_provenance.
• NP724307.RAu_51OajLdm6oZSiJxUcsMHZvzWn8wKrgXnsXGc1JbQc130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724307.RAu_51OajLdm6oZSiJxUcsMHZvzWn8wKrgXnsXGc1JbQc130_provenance.
• NP724318.RAmQYVUXDx--Gb9A7pNR1fSLJ-KzUOJP4mCkePMhm8hoA130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724318.RAmQYVUXDx--Gb9A7pNR1fSLJ-KzUOJP4mCkePMhm8hoA130_provenance.
• NP1414033.RAof4fr04Zkm644riVPhKItL-2HNeWJjCkH8y42t_nNNA130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414033.RAof4fr04Zkm644riVPhKItL-2HNeWJjCkH8y42t_nNNA130_provenance.
• NP1414036.RAhWhjjwvuVf3gecr80w4aMsRGTz_sAArhZ5dw2BUjPog130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414036.RAhWhjjwvuVf3gecr80w4aMsRGTz_sAArhZ5dw2BUjPog130_provenance.
• NP1414038.RAglKvXZm_SSlq5uHDV-x5P2akF-mYVR3wlOEgoDgjP2k130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414038.RAglKvXZm_SSlq5uHDV-x5P2akF-mYVR3wlOEgoDgjP2k130_provenance.
• NP724311.RAGqqe4Sz5gMe9qGOSCXEtpeKtYwvzIbODQBag1n_1DXE130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724311.RAGqqe4Sz5gMe9qGOSCXEtpeKtYwvzIbODQBag1n_1DXE130_provenance.
• NP724313.RAMRrt1qauNNWS5Z2uqPp_k5snFkU6i1qzDdl9mVr3SL8130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724313.RAMRrt1qauNNWS5Z2uqPp_k5snFkU6i1qzDdl9mVr3SL8130_provenance.
• NP724317.RAO6woLRZT1m68iY3LP4LZjBrQU0pRQUA-CW2MPqMzIAo130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP724317.RAO6woLRZT1m68iY3LP4LZjBrQU0pRQUA-CW2MPqMzIAo130_provenance.
• NP1414039.RAHK4041Phd1oyxOHICOP-YUpweHA35RXgW2x-8K-wPLQ130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414039.RAHK4041Phd1oyxOHICOP-YUpweHA35RXgW2x-8K-wPLQ130_provenance.
• NP1414030.RA5zzkcsC7YWAid9yrSVBxXJ6Pn7RFbf36OtAlaGAYZT0130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414030.RA5zzkcsC7YWAid9yrSVBxXJ6Pn7RFbf36OtAlaGAYZT0130_provenance.
• NP1414037.RA4Sx5wS2CUfstpezz0RFO-Yrwkvb83ypYviOpEUBAIDg130_assertion description "[The von Hippel-Lindau (VHL) tumour suppressorgene product is believed to be involved in the down-regulation of transcriptional elongation by preventing the association of elongin B and C with the catalytic subunit elongin A. Alterations in the human VHL gene lead to VHL disease which is associated with various rare neoplasias, including haemangioblastoma of the central nervous system, retinal angioma, clear cell renal carcinoma and pheochromocytoma.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1414037.RA4Sx5wS2CUfstpezz0RFO-Yrwkvb83ypYviOpEUBAIDg130_provenance.